TWiV 970: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China, canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event, two masks can be worse than one: N95 respirator failure caused by an overlying face mask, airflow patterns in double-occupancy patient rooms may contribute to roommate-to-roommate transmission of severe SARS-CoV-2, clinical validation of a novel T-Cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection, antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant, VV116 versus Nirmatrelvir–Ritonavir for oral treatment of Covid-19, Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support, FDA approves Roche's Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults, structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction, persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium, epidemiology of long COVID in US adults, persistent symptoms and sequelae after SARS-CoV-2 infection not requiring hospitalization, and outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Modeling the adjustment of COVID-19 response and exit in China (Nature)
- Canine real-time detection of SARS-CoV-2 infections in mass screening events (BMJ)
- N95 respirator failure caused by an overlying face mask (ICHE)
- Airflow in patient rooms may contribute to transmission of severe SARS-CoV-2 (CID)
- Clinical validation of a T-Cell receptor for identification of recent or prior SARS-CoV-2 infection (CID)
- Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages (Cell)
- VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19 (NEJM)
- Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system (ACP)
- Molnupiravir as early treatment for adults with COVID-19 (The Lancet)
- Higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support (medRxiv)
- FDA approves Tocilizumab for the treatment of COVID-19 in hospitalized adults (Roche)
- Structural brain changes in post-acute COVID-19 patients with olfactory dysfunction (Annals)
- Paxlovid patient eligbiliity screening checklist (FDA)
- Persistent post–COVID-19 smell loss association (Science)
- Epidemiology of long COVID in US adults (CID)
- Persistent symptoms & sequelae after SARS-CoV-2 infection not requiring hospitalization (OFID)
- Outpatient treatment of COVID-19 with metformin, ivermectin, and fluvoxamine & the development of long COVID (medRxiv)
- Contribute to our MicrobeTV fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 970
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update Dr. Griffin discusses modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China, canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event, two masks can be worse than one: N95 respirator failure caused by an overlying face mask, airflow patterns in double-occupancy patient rooms may contribute to roommate-to-roommate transmission of severe SARS-CoV-2, clinical validation of a novel T-Cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection, antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant, VV116 versus Nirmatrelvir–Ritonavir for oral treatment of Covid-19, Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support, FDA approves Roche's Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults, structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction, persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium, epidemiology of long COVID in US adults, persistent symptoms and sequelae after SARS-CoV-2 infection not requiring hospitalization, and outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Modeling the adjustment of COVID-19 response and exit in China (Nature)
- Canine real-time detection of SARS-CoV-2 infections in mass screening events (BMJ)
- N95 respirator failure caused by an overlying face mask (ICHE)
- Airflow in patient rooms may contribute to transmission of severe SARS-CoV-2 (CID)
- Clinical validation of a T-Cell receptor for identification of recent or prior SARS-CoV-2 infection (CID)
- Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages (Cell)
- VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19 (NEJM)
- Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system (ACP)
- Molnupiravir as early treatment for adults with COVID-19 (The Lancet)
- Higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support (medRxiv)
- FDA approves Tocilizumab for the treatment of COVID-19 in hospitalized adults (Roche)
- Structural brain changes in post-acute COVID-19 patients with olfactory dysfunction (Annals)
- Paxlovid patient eligbiliity screening checklist (FDA)
- Persistent post–COVID-19 smell loss association (Science)
- Epidemiology of long COVID in US adults (CID)
- Persistent symptoms & sequelae after SARS-CoV-2 infection not requiring hospitalization (OFID)
- Outpatient treatment of COVID-19 with metformin, ivermectin, and fluvoxamine & the development of long COVID (medRxiv)
- Contribute to our MicrobeTV fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 970
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.